A cyclic peptide composed of five
tryptophan, four arginine, and
one cysteine [W5R4C] was synthesized. The peptide
was evaluated for generating cyclic peptide-capped selenium nanoparticles
(CP–SeNPs) in situ. A physical mixing of the cyclic peptide
with SeO3–2 solution in water generated
[W5R4C]–SeNPs via the combination of
reducing and capping properties of amino acids in the peptide structure.
Transmission electron microscopy (TEM) images showed that [W5R4C]–SeNPs were in the size range of 110–150
nm. Flow cytometry data revealed that a fluorescence-labeled phosphopeptide
(F′-PEpYLGLD, where F′ = fluorescein) and an anticancer
drug (F′-dasatinib) exhibited approximately 25- and 9-times
higher cellular uptake in the presence of [W5R4C]–SeNPs than those of F′-PEpYLGLD and dasatinib alone
in human leukemia (CCRF-CEM) cells after 2 h of incubation, respectively.
Confocal microscopy also exhibited higher cellular delivery of F′-PEpYLGLD
and F′-dasatinib in the presence of [W5R4C]–SeNPs compared to the parent fluorescence-labeled drug
alone in human ovarian adenocarcinoma (SK-OV-3) cells after 2 h of
incubation at 37 °C. The antiproliferative activities of several
anticancer drugs doxorubicin, gemcitabine, clofarabine, etoposide,
camptothecin, irinotecan, epirubicin, fludarabine, dasatinib, and
paclitaxel were improved in the presence of [W5R4C]–SeNPs (50 μM) by 38%, 49%, 36%, 36%, 31%, 30%, 30%,
28%, 24%, and 17%, respectively, after 48 h incubation in SK-OV-3
cells. The results indicate that CP–SeNPs can be potentially
used as nanosized delivery tools for negatively charged biomolecules
and anticancer drugs.